%0 Journal Article %A X., Long %A L., Qi %A X., Zu %A Y., Li %A W., He %A S., Pi %A X., Chen %A K., Zhou %A X., Hu %A M., Chen %D 2016 %T Supplementary Material for: Prevention of Recurrent Bladder Tumors after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: An Individualized Selection Strategy Based on Patient Risk Stratification Is Needed %U https://karger.figshare.com/articles/journal_contribution/Supplementary_Material_for_Prevention_of_Recurrent_Bladder_Tumors_after_Nephroureterectomy_for_Primary_Upper_Urinary_Tract_Urothelial_Carcinoma_An_Individualized_Selection_Strategy_Based_on_Patient_Risk_Stratification_Is_Needed/4233158 %R 10.6084/m9.figshare.4233158.v2 %2 https://karger.figshare.com/ndownloader/files/6903746 %K Intravesical chemotherapy %K Neoplasm recurrence %K Urothelium %K Urinary bladder %K Urinary tract %X Objective: To evaluate the efficacies of different chemotherapy regimens in different risk sub-groups for the prevention of bladder recurrence after radical nephroureterectomy (RNU). Materials and Methods: Between 2004 and 2012, we recruited 685 patients who underwent RNU for upper tract urothelial carcinoma at 4 Chinese institutions. We assessed whether the type of intravesical chemotherapy regimen affected the bladder recurrence rate in patients with different risk levels after RNU. Results: For all patients, the bladder recurrence rate was lower with intravesical chemotherapy than without, but no significant differences were found between the 2 intravesical chemotherapy regimens (single dose or relatively long-term therapy). We used multivariate analysis to define the risk factors for bladder recurrence and stratified patients into low-, intermediate-, and high-risk sub-groups accordingly. The bladder recurrence rate in the low-risk patients was not significantly different between patients with or without intravesical chemotherapy. However, in the intermediate-risk and high-risk patients, the rate was greater in patients without intravesical chemotherapy than in patients with. Furthermore, the rate was not significantly different between the 2 intravesical chemotherapy regimens in the intermediate-risk patients, while the efficacy of the relatively long-term regimen in high-risk patients remains unclear. Conclusions: Our study showed that an individualized strategy based on patient risk stratification is needed. %I Karger Publishers